Appendiceal Neoplasms

Rare, heterogeneous group of epithelial and nonepithelial tumors (age-adjusted incidence ~6/1,000,000/year; found in ~1% of appendectomy specimens). Usually diagnosed postoperatively after presenting like acute appendicitis — preoperative diagnosis is difficult, and even when suspected intraoperatively, associated inflammation can preclude definitive diagnosis at the time. Prognosis depends heavily on histologic subtype and grade (10-year survival ranges 10-90% across subtypes/grades).

Staging (AJCC 8th edition)

Standard TNM framework, with appendix-specific features:

• Tis(LAMN): a unique in-situ category for low-grade appendiceal mucinous neoplasm confined by the muscularis propria.
• M1a/M1b/M1c: distinguishes acellular intraperitoneal mucin (M1a) from cellular peritoneal mucinous deposits containing tumor cells (M1b) from metastasis outside the peritoneum (M1c) — a clinically important distinction for mucinous disease specifically.

The five histopathologic subtypes

1. Mucinous appendiceal neoplasms (MANs) / pseudomyxoma peritonei (PMP)

50% of tumor volume is extracellular mucin. Graded by the PSOGI classification (adopted into AJCC 8th ed.): LAMN (low-grade cytology, no infiltrative invasion) → high-grade appendiceal mucinous neoplasm (high-grade cytology, still no infiltrative invasion) → mucinous adenocarcinoma (infiltrative invasion present, itself graded 1-3).

• Management: nonperforated grade 1 (low-grade) MAN completely excised by appendectomy alone may undergo surveillance rather than further resection. Grade 2/3 MANs should get right hemicolectomy for staging/oncologic purposes. LN positivity rates track grade tightly: grade 1 ~1%, grade 2 ~17%, grade 3 ~72% (corresponding 5-yr survival 91% / 61% / 23%).
• PMP (peritoneal spread of mucinous disease — “jelly belly”) is graded low-grade / high-grade / signet-ring by the same PSOGI system. Treated with CRS/HIPEC in well-selected patients — median OS 51-156 months, 10-yr OS up to 70% in modern series. No role for systemic chemotherapy in low-grade MAN/PMP; fluoropyrimidine-based regimens (similar to colorectal cancer) generally used for grade 2/3.
• Low-grade MAN with localized acellular peritoneal mucin carries low risk of progressing to PMP (4%); with cellular mucin, risk is much higher (40%) — matters for surveillance intensity.

2. Neuroendocrine neoplasms (NENs)

Formerly called “carcinoid” (outdated term). Arise from subepithelial neuroendocrine cells concentrated at the appendiceal tip. WHO 2019 grades by mitotic rate + Ki-67 index: NET G1 (well-differentiated, low grade) → NET G2 → NET G3, vs. poorly-differentiated NEC, vs. mixed neuroendocrine-nonneuroendocrine neoplasm (MiNEN).

• Management is size-driven: <1cm → appendectomy alone sufficient (no further follow-up needed if completely resected and node-negative). >2cm, or tumors involving the appendiceal base → right hemicolectomy generally recommended. 1-2cm zone: individualized based on other risk features (some investigators question whether hemicolectomy actually improves OS even here).
• LN involvement scales sharply with size: 15% (≤1cm), 47% (1-2cm), 86% (>2cm) — corresponding 10-yr survival for node-positive disease 100% / 92% / 91% respectively (i.e., even node-positive well-differentiated NETs have a good prognosis).
• Advanced/metastatic disease: somatostatin analogs are tumoristatic — octreotide (Rinke 2009 - PROMID Trial: median time-to-progression 14.3 vs 6.0 months in treatment-naive midgut NETs) and lanreotide (Caplin 2014 - CLARINET Trial: median PFS not reached vs 18.0 months in nonfunctioning enteropancreatic NETs) — used for disease control rather than downstaging. Everolimus (Yao 2016 - RADIANT-4 Trial: median PFS 11.0 vs 3.9 months in advanced non-functional lung/GI NETs; RADIANT-2, in functioning NETs, is not yet independently ingested) improves PFS in progressive/advanced NETs. Peptide receptor radionuclide therapy with Lu-177-DOTATATE (Strosberg 2017 - NETTER-1 Trial: 79% lower risk of progression/death vs high-dose octreotide) improved PFS and response for somatostatin-receptor-positive advanced midgut NETs; NCCN recommends it for advanced/metastatic somatostatin-receptor-positive GI NETs. These four trials enrolled small-bowel/midgut and other GI NET populations rather than appendiceal NETs specifically — see Small Bowel Neuroendocrine Tumors (NETs)‘s Medical therapy section for the full primary-source synthesis; figures here are extrapolated to appendiceal NENs by extension of the same somatostatin-receptor-positive GI NET biology, per Hoehn’s review.

3. Goblet cell adenocarcinoma (GCA)

Renamed from “goblet cell carcinoid” — the neuroendocrine component is now understood to be minor relative to the mixed adenocarcinoma component. More aggressive than typical NETs: frequent transmural invasion, nodal involvement, peritoneal metastasis. Graded 1-3 by proportion of high-grade histologic pattern (<25% / 25-50% / >50%).

• Management: right hemicolectomy recommended for essentially all diagnosed GCA (small series questioning this for tumors <1cm are not strong enough to change consensus).
• Grade correlates strongly with survival: grade 3 median survival 33 months vs. 98 months for grade 1/2 in one series (5-yr survival 23% vs 54%).
• Peritoneal spread treated with CRS/HIPEC, similar rationale to MAN/PMP.

4. Colonic-type (nonmucinous) adenocarcinoma

Resembles other GI adenocarcinomas; treated per colon cancer treatment algorithms (no appendix-specific systemic therapy guidelines exist). Given the real lymph node risk even in small tumors (19% for >1cm, comparable to primary colon adenocarcinoma), right hemicolectomy is recommended regardless of tumor size for invasive disease. Presents at a more advanced stage than typical colon cancer on average: T3/T4 in 68% of standard AA, node involvement 29%, metastatic disease 22%.

5. Signet ring cell adenocarcinoma

Most aggressive subtype. Despite a similar T-stage distribution to standard appendiceal adenocarcinoma, presents with much more advanced disease overall (T3/T4 91%, N1 61%, M1 56%) and has markedly worse survival — median 24 months vs. 48 months for standard AA. Nearly all metastatic signet ring disease is peritoneal, with only ~10% at distant (non-peritoneal) sites. Genetically distinct from typical colorectal cancer (lower KRAS/APC/PIK3CA mutation rates) despite the worse prognosis.

Cross-cutting management notes

• All patients with any invasive appendiceal adenocarcinoma (colonic-type, signet ring, or grade 2/3 MAN) should undergo formal right hemicolectomy (see Colon Cancer Resection for technique) for staging and oncologic control, and a metastatic workup similar to colon cancer (CT chest/abdomen/pelvis, CEA).
• Peritoneal-spread disease (from any epithelial subtype) is managed with CRS/HIPEC in well-selected patients at experienced centers — see that page for the controversies (HIPEC’s actual added benefit, PCI cutoffs, agent choice).
• Given rarity and the lack of randomized data for most scenarios, this source repeatedly stresses that patients should be evaluated at high-volume institutions by surgical/medical oncologists familiar with these specific tumor types — general colorectal cancer protocols don’t map cleanly onto all five subtypes.

Open items / gaps

• PROMID, CLARINET, RADIANT-4, and NETTER-1 primary publications are now ingested (2026-08-19 lint pass) and cited above — RADIANT-2 is still not independently ingested. Note these trials enrolled midgut/GI NET populations generally, not appendiceal NETs specifically; the wiki has no appendiceal-NET-specific trial data, only Hoehn’s review extrapolating general NET-therapy evidence to this subtype.
• Right hemicolectomy technique is covered on Colon Cancer Resection (a colon-cancer-focused procedure page) rather than a dedicated appendiceal-specific page — cross-linked above; no gap in content, just previously missing the link.
• No dedicated page yet on general appendiceal anatomy/embryology relevant to why NENs cluster at the appendiceal tip.